From Horizon scanning to the new HTA Regulation
Le nuove norme del panorama legislativo impongono una elevata attenzione all’accesso dei farmaci nel prossimo futuro. Dal 1° gennaio 2025 diventerà operativo il nuovo regolamento
12 June 2023
Le nuove norme del panorama legislativo impongono una elevata attenzione all’accesso dei farmaci nel prossimo futuro. Dal 1° gennaio 2025 diventerà operativo il nuovo regolamento
È stata ratificata lunedì, 24 maggio 2023, in Conferenza Stato-Regioni, l’approvazione del Piano Nazionale Malattie Rare 2023-2026, realizzato dopo 7 anni di lavori, con il
In 2020, AIFA introduced the new simplified P&R negotiation procedures: simplified price and reimbursement procedure for drug negotiations
The 5% Fund for rare diseases, which allows access to medicines that are not yet marketed in Italy and represent a hope of cure for
On 10 March 2022, the 'National Report on the Use of Antibiotics in Italy -2020' was presented on AIFA's YouTube channel.
On 7 January 2022, the Council of State (15 March 2021, No. 3095) issued its judgment on the appeal filed by Bayer against the
On 30 November 2021, AIFA defined the new access criteria for Law 326/2003. This law was supplemented by the Law of 10 November 2021
On 26 May 2021, the Chamber of Deputies, after more than two years of work in the Social Affairs Commission, approved the bill promoting the
NOMOS Centro Studi Parlamentari and Pharma Value produced a special report on drug evaluation commissions, namely the Technical Scientific Commission and the
AIFA Commissions (CTS and CPR) expire in September. NOMOS parliamentary study centre and Pharma Value take stock of the rules for the renewal of the
